Description
LUNSUMIO (mosunetuzumab-axgb) injection
FDA grants accelerated approval to mosunetuzumab-axgb for relapsed or refractory follicular lymphoma.
On December 22, 2022, the Food and Drug Administration (FDA) granted accelerated approval to mosunetuzumab-axgb (Lunsumio, Genentech, Inc.), a bispecific CD20-directed CD3 T-cell engager for adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
Get Access to LUNSUMIO (mosunetuzumab-axgb) injection In India
On request it available to patient and doctors. Medvitaz Pharma is equipped to facilitate the distribution of LUNSUMIO (mosunetuzumab-axgb) injection (prescription medications) worldwide and throughout India upon completion of necessary legal procedures, if applicable.
To inquire about the price of either the branded medication “LUNSUMIO (mosunetuzumab-axgb) injection” or the generic version “mosunetuzumab-axgb injection” for personal use under patient-specific treatment in various cities including Delhi, Mumbai, Kolkata, Chennai, Bangalore, Hyderabad, Ahmedabad, Pune, Surat, Jaipur, Coimbatore, Noida, Gurgaon, Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim, and others in India, please fill out the request form. Upon receiving your request and assessing the delivery process, we will provide you with an estimated price for the medication within 24 hours.
For any inquiries or assistance, please reach out to our Patient Support Team. We are available to assist you from Monday to Friday, between 9:00 and 19:00 IST. You can contact us via email at [email protected], toll-free at +91 8750295029, or through WhatsApp at +91-8750295029.